Top in hem/onc: Checkpoint inhibitor indications, loneliness of childhood cancer survivors
Click Here to Manage Email Alerts
Last week, an FDA panel voted against maintaining a gastric cancer indication for pembrolizumab and a hepatocellular carcinoma indication for nivolumab. It was the top story in hematology/oncology.
Another top story revealed childhood cancer survivors have an elevated risk for feelings of loneliness due to isolation during their cancer experience. The top three predictors of loneliness included parents’ marital status at time of treatment, type of treatment and race.
Read these and more top stories in hematology/oncology below:
FDA panel votes to maintain four of six indications for checkpoint inhibitors under review
The Oncologic Drugs Advisory Committee voted to maintain four of six indications for checkpoint inhibitors that have received FDA accelerated approval. Read more.
Childhood cancer survivors at risk for loneliness
Some childhood cancer survivors appeared to have an elevated risk for loneliness, according to study results presented during the virtual Oncology Nursing Society Congress. Read more.
Immune checkpoint inhibitors linked to high thromboembolism risk in patients with cancer
Patients with cancer may be at high risk for venous thromboembolism and arterial thromboembolic events while undergoing treatment with immune checkpoint inhibitors, according to study results published in Blood. Read more.
Depressive symptoms, other health conditions may contribute to fatigue among cancer survivors
Interventions that target depressive symptoms and self-rated health conditions may reduce fatigue among cancer survivors, according to study results presented at the virtual Oncology Nursing Society Congress. Read more.
Stereotactic body radiotherapy appears safe for treatment of multiple metastases
Treatment with stereotactic body radiotherapy resulted in no protocol-defined dose-limiting toxicities among patients with oligometastatic breast, prostate or non-small cell lung cancers, according to results of the phase 1 NRG-BR001 trial. Read more.